Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-02-05
2009-06-02
Rao, Manjunath N (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600
Reexamination Certificate
active
07541337
ABSTRACT:
Compositions and methods for treating peripheral artery disease in a patient are provided. Compositions comprise recombinant fibroblast growth factor-2. Fibroblast growth factor, such as FGF-2, is administered in therapeutically effective amounts to treat or prevent peripheral artery disease including claudication and critical limb ischemia. Pharmaceutical compositions comprising a therapeutically effective amount of FGF-2 and a pharmaceutically acceptable carrier are also provided. The methods of the invention to treat peripheral artery disease and claudication comprise administering at least a single dose of a pharmaceutical composition comprising the FGF, such as FGF-2, via intra-arterial, intravenous, or intramuscular infusion to the patient. It is recognized that increased benefits may result from multiple dosing, including intermittent dosing.
REFERENCES:
patent: 5604293 (1997-02-01), Fiddes et al.
patent: 5792453 (1998-08-01), Hammond et al.
patent: 5852177 (1998-12-01), Senoo et al.
patent: 5879713 (1999-03-01), Roth et al.
patent: 5941868 (1999-08-01), Kaplan et al.
patent: 6440934 (2002-08-01), Whitehouse
patent: 6451303 (2002-09-01), Whitehouse et al.
patent: 7112560 (2006-09-01), Whitehouse
patent: 7186407 (2007-03-01), Whitehouse
patent: 2003/0166550 (2003-09-01), Whitehouse
patent: 2006/0025343 (2006-02-01), Whitehouse et al.
patent: 2007/0142283 (2007-06-01), Whitehouse
patent: WO 00/13701 (2000-03-01), None
patent: WO 00/21548 (2000-04-01), None
Baffour, R., et al., “Enhanced Angiogenesis and Growth of Collaterals by In Vivo Administration of Recombinant Basic Fibroblast Growth Factor in a Rabbit Model of Acute Lower Limb Ischemia: Dose-Response Effect of Basic Fibroblast Growth Factor,”Journal of Vascular Surgery, Aug. 1992, pp. 181-191, vol. 16(2).
Baumgartner, I., and J.M. Isner, “Stimulation of Peripheral Angiogenesis by Vascular Endothelial Growth Factor (VEGF),”VASA, Nov. 1998, pp. 201-206, vol. 27(4).
Cooke, J.P., et al., “Fibroblast Growth Factor as Therapy for Critical Limb Ischemia: A Case Report,”Vascular Medicine, 1999, pp. 89-91, vol. 4.
Fisher, R.K., and P.L. Harris, “Epidemiological and Economic Considerations in the Critically Ischemic Limb,”Critical Limb Ischemia, Jul. 1999, pp. 19-25, Futura Publishing Co., New York.
Gerwins, P., et al., “Function of Fibroblast Growth Factors and Vascular Endothelial Growth Factors and Their Receptors in Angiogenesis,”Critical Reviews in Oncology/Hematology, 2000, pp. 185-194, vol. 34(3), Elsevier Science Publishers Ltd., Ireland.
Hiatt, W.R., et al., “Clinical Trials for Claudication—Assessment of Exercise Performance, Functional Status, and Clinical End Points,”Circulation, Aug. 1, 1995, pp. 614-621, vol. 92(3).
Lazarous, D.F., et al., “Basic Fibroblast Growth Factor in Patients with Intermittent Claudication: Results of a Phase I Trial,”Journal of the American College of Cardiology, Oct. 2000, pp. 1239-1244, vol. 36(4), Elsevier Science Inc.
Lazarous, D.F., et al., “Effect of Basic Fibroblast Growth Factor on Lower Extremity Blood Flow in Patients with Intermittent Claudication: Preliminary Results,”Supplement to Circulation, Abstracts from the 71stScientific Sessions, Oct. 27, 1998, p. I-456, Abstract No. 2398, vol. 98(17), Supplement I.
Moyer, et al., “bFGF: A Potential Therapeutic Agent for the Treatment of Acute Neurodegenerative and Vascular Insufficiency,”Expert Opinion on Therapeutic Patents, 1998, pp. 1425-1446, vol. 8 (11).
Pantely, G.A., and J.M. Porter, “Therapeutic Angiogenesis: Time for the Next Phase,”Journal of the American College of Cardiology, Oct. 2000, pp. 1245-1247, vol. 36(4), Elsevier Science Inc.
Regensteiner, J.G., et al., “Evaluation of Walking Impairment by Questionnaire in Patients with Peripheral Arterial Disease,”Journal of Vascular Medicine and Biology, Jun. 1990, pp. 142-152, vol. 2(3).
Santilli, J.D., and S.M. Santilli, “Chronic Critical Limb Ischemia: Diagnosis, Treatment and Prognosis,”American Family Physician, Apr. 1, 1999, pp. 1899-1908, vol. 59(7).
Weitz, J.I., et al., “Diagnosis and Treatment of Chronic Arterial Insufficiency of the Lower Extremities: A Critical Review,”Circulation, 1996, pp. 3026-3049, vol. 94.
Yang, H.T., et al., “Basic Fibroblast Growth Factor Increases Collateral Blood Flow in Rats with Femoral Arterial Ligation,”Circulation Research, Jul. 1996, pp. 62-69, vol. 79(1).
Yang, H.T., and Y. Feng, “bFGF Increases Collateral Blood Flow in Aged Rats with Femoral Artery Ligation,”Am. J. Physiol. Heart Circ. Physiol., 2000, pp. H85-H93, vol. 278, American Physiological Society, USA.
Yang, H.T., et al., “Efficacy and Specificity of bFGF Increased Collateral Flow in Experimental Peripheral Arterial Insufficiency,”Am. J. Physiol. Heart Circ. Physiol., 2000, pp. H1966-H1973, vol. 278, American Physiological Society, USA.
Yang, H.T., et al., “Exercise Training Enhances Basic Fibroblast Growth Factor-Induced Collateral Blood Flow,”Am. J. Physiol. Heart Circ. Physiol., 1998, pp. H2053-H2061, vol. 274, American Physiological Society, USA.
Alston & Bird LLP
Gamett Daniel C
Novartis Vaccines and Diagnostics Inc.
Rao Manjunath N
LandOfFree
Methods and compositions for the treatment of peripheral... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the treatment of peripheral..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the treatment of peripheral... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4074531